Spots Global Cancer Trial Database for ccrcc
Every month we try and update this database with for ccrcc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors | NCT04417465 | Advanced Solid ... | ABBV-CLS-579 PD-1 inhibitor VEGFR TKI | 18 Years - | Calico Life Sciences LLC | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma | NCT03108066 | VHL Gene Mutati... VHL VHL Syndrome VHL Gene Inacti... Von Hippel Von Hippel-Lind... Von Hippel's Di... Von Hippel-Lind... Clear Cell Rena... Clear Cell RCC ccRCC | PT2385 Tablets | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | NCT04810078 | Clear Cell Rena... | Nivolumab and r... Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | NCT01649180 | Renal Cell Carc... | Axitinib | 18 Years - | PrECOG, LLC. | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | NCT02293980 | ccRCC RCC Kidney Cancer Clear Cell Rena... Renal Cell Carc... | MK-3795 Nivolumab Cabozantinib Bezlutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | NCT06234605 | Renal Cell Carc... | HC-7366 Belzutifan | 18 Years - | HiberCell, Inc. | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | NCT03875313 | Solid Tumor Clear Cell Rena... TNBC - Triple-N... Colorectal Canc... CRC RCC ccRCC | CB-839 Talazoparib | 18 Years - | Calithera Biosciences, Inc | |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | NCT06234605 | Renal Cell Carc... | HC-7366 Belzutifan | 18 Years - | HiberCell, Inc. | |
| Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05520099 | Colorectal Canc... Head and Neck S... Non Small Cell ... Cutaneous Melan... Endometrial Can... Urothelial Carc... Clear Cell Rena... | Core Needle or ... | 18 Years - | Elephas | |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | NCT05121948 | Squamous Cell C... Colo-rectal Can... Non Small Cell ... Transitional Ce... Other Solid Tum... Clear Cell Rena... | HC-7366 | 18 Years - | HiberCell, Inc. | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China | |
| Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC | NCT06114940 | Neoplasms Kidney Neoplasm... Urologic Neopla... Urogenital Neop... Female Urogenit... Urogenital Dise... Kidney Diseases Urologic Diseas... Male Urogenital... Carcinoma Carcinoma, Rena... Antineoplastic ... Immune Checkpoi... | Toripalimab Lenvatinib | 18 Years - | Jinling Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
